RECOMBINANT HEPATITIS B VACCINE

This brand name is authorized in Nigeria.

Active ingredients

The drug RECOMBINANT HEPATITIS B VACCINE contains one active pharmaceutical ingredient (API):

1	Hepatitis B, purified antigen
	Hepatitis B vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Hepatitis B vaccine has been recognized as the first anti-cancer vaccine because it can prevent primary liver cancer.
	Read more about Hepatitis B, purified antigen

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-100103	Suspension for injection	Recombinant Hepatitis B Vaccine 0.5 mL (Pediatric) INJ_SUSP 10 mcg/0.5 mL 0.5 mL x 10's (in Pre-filled syringes) + 1 sterile needle (25G x 5/8')	Suspension for injection. White suspension, packaged in prefill injection device	04/06/2023
A6-100104	Suspension for injection	Recombinant Hepatitis B Vaccine 1.0 mL (Adult) INJ_SUSP 20 mcg/mL 1 mL x 10's (in Pre-filled syringes) + 1 sterile needle (25G x 1")	Suspension for injection. White suspension, packaged in prefill injection device	04/06/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07BC01	Hepatitis B, purified antigen	J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BC Hepatitis vaccines
Discover more medicines within J07BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A6-100103, A6-100104